<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45044">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01669226</url>
  </required_header>
  <id_info>
    <org_study_id>V01-2009-03</org_study_id>
    <nct_id>NCT01669226</nct_id>
  </id_info>
  <brief_title>First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer</brief_title>
  <acronym>AICE</acronym>
  <official_title>A Phase II,Randomized Study of an Addition Intraperitoneal Cisplatin and Etoposide to Standard First-line Therapy in Stage IIIC and Stage IV Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (EOC, FTC, PPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai JiaoTong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soochow University (Jiangsu)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji University (Shanghai)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Gynecologic Oncology Group</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the role of an additional intraperitoneal
      chemotherapy with cisplatin and etoposide in bulky advanced epithelial ovarian cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This exploratory trial is to compare the efficacy of sequential chemotherapy,
      intraperitoneal chemotherapy followed by intravenous chemotherapy, versus intravenous
      chemotherapy alone in the first-line therapy for ovarian cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>12-month disease non-progression rate</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to 120 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completion rate of intraperitoneal chemotherapy.</measure>
    <time_frame>up to 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessments</measure>
    <time_frame>baseline; 4th week of intraperitoneal,chemotherapy, 6th cycle of intravenous chemotherpy, 3, 6, and 12 months after first-line chemotherapy.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 120 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse effects</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 5 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Bulky Stage IIIC and IV Epithelial Ovarian Cancer,</condition>
  <condition>Fallopian Tube Cancer,</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Regimen B, PEip and TCiv therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly IP cisplatin plus etoposide followed by IV paclitaxel plus carboplatin or docetaxel plus carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen A: Standard TCiv therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV paclitaxel plus carboplatin or docetaxel plus carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEip (weekly) and TCiv</intervention_name>
    <description>IP: cisplatin 50mg/m2 and etoposide 100mg/m2, weekly, 4 times; 14 days later IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5</description>
    <arm_group_label>Regimen B, PEip and TCiv therapy</arm_group_label>
    <other_name>platinum</other_name>
    <other_name>VP 16</other_name>
    <other_name>taxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TCiv</intervention_name>
    <description>IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5</description>
    <arm_group_label>Regimen A: Standard TCiv therapy</arm_group_label>
    <other_name>taxane</other_name>
    <other_name>platinum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years to ≤ 75 years.

          -  Epithelial ovarian cancer with pathology confirmed stage IIIc or IV, expect for lymph
             node metastasis alone

          -  Optimal cytoreductive surgery, including hysterectomy, bilateral
             salpinges-oophorectomy, omentectomy, and resection of all metastatic lesions, with a
             residual disease no more than 1cm

          -  Available to receive intraperitoneal chemotherapy 5-10 days postoperative, or no more
             than postoperative 14 days for those with bowel resection.

          -  ECOG performance 0-2.

          -  No more than 3 cycles of chemotherapy prior to surgery.

          -  Laboratory testing within 7 days of registration: hematopoietic: absolute neutrophil
             count greater than 1,500/mm3; Platelet count greater than 100,000/mm3. Hepatic:
             bilirubin less than 1.25 times upper limit of normal (ULN); Bilirubin &lt; 2.0, SGPT
             less than 2 times ULN. Renal: creatinine less than 1.6 mg/dL, OR creatinine clearance
             greater than 40 mL/min.

          -  Comply with intraperitoneal chemotherapy and follow-up.

          -  Written informed consent.

        Exclusion Criteria:

          -  Low-malignant potential ovarian tumor.

          -  Laboratory testing insufficiency. Hemoglobin &lt; 10 g/dL. Renal insufficiency with
             serum creatinine &gt; 1.6.

          -  Bone marrow dysfunction: absolute neutrophil count less than 1,500/mm3; Platelet
             count less than 80,000/mm3.

          -  Active infection.

          -  Clinically significant gastrointestinal abnormalities.

          -  Active coronary artery disease, cerebrovascular disease, restrictive or obstructive
             pulmonary disease, or congestive heart failure.

          -  Other condition that could interfere with provision of informed consent, compliance
             to study procedures, or follow-up.

          -  Prior invasive malignancies within the last 5 years showing activity of disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rongyu Zang, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Gynecologic Oncology Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Tang, MD,PhD</last_name>
    <phone>+862164175590</phone>
    <email>fudanGOG@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuting Luan, RN</last_name>
    <phone>+862164175590</phone>
    <email>yutingluan@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Suzhou Municipal Hospital</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mi Zhang, MD</last_name>
      <phone>+8613584887057</phone>
      <email>z_m_7_0@yahoo.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuxi Cancer Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shan Su, MD</last_name>
      <phone>+8613861768827</phone>
      <email>ssli2004@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Frist Maternity and Infant Hospital Affiliated to Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xipeng Wang, MD,PhD</last_name>
      <email>xipengwang@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ren Ji Hospital Affiliated to Shanghai JiaoTong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lihua Qiu, MD,PhD</last_name>
      <phone>+862158752345</phone>
      <email>lilyqiulh@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuting Luan, RN</last_name>
      <phone>+862164175590</phone>
      <email>yutingluan@163.com</email>
    </contact>
    <investigator>
      <last_name>Rongyu Zang, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 2, 2013</lastchanged_date>
  <firstreceived_date>August 8, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian Cancer</keyword>
  <keyword>intraperitoneal chemotherapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
